Namzaric (Donepezil/Memantine) for Alzheimer's | myALZteam

Connect with others who understand.

sign up Log in
About myALZteam
Powered By

Namzaric is a prescription drug approved by the Food and Drug Administration (FDA) to treat moderate to severe cases of Alzheimer’s disease.

Namzaric is a combination drug composed of the drugs Memantine, the active ingredient in Namenda, and Donepezil, the active ingredient in Aricept. Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist. Memantine is believed to work by regulating the amount of glutamate, a neurotransmitter, in the brain. Donepezil is a cholinesterase inhibitor. Donepezil is believed to work by slowing the breakdown of a neurotransmitter in the brain.

How do I take it?
Prescribing information states that Namzaric is generally taken once daily in the evening.

Namzaric comes as a capsule.

Side effects
The FDA-approved label for Namzaric lists common side effects including headache, diarrhea, dizziness, and bruising.

Rare but serious side effects listed for Namzaric include seizures, worsening of lung problems, trouble urinating, slow heartbeat, stomach problems, and fainting.

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in